This “Fundraising for the Foundation” panel discusses their Fundraise for Meso events, best practices, and answered questions from moderator Katie Jamieson, co-chair of the Community…
Andreas Rimner, MD discusses a phase 3 clinical trial that is testing the addition of IMRT (intensity-modulated radiotherapy) to pemetrexed (Alimta)/platinum based therapy for pleural…
Sean Drake, MD provides an overview of vaccinations — tetanus, diphtheria and pertussis, hepatitis A, hepatitis B, pneumonia, pneumovax, prevnar 13, shingles, shingrix, influenza (flu),…
Arkadiusz Dudek, MD, PhD, discusses the Phase 2 Nivolumab (Opdivo) + Ramucirumab clinical trial for previously-treated mesothelioma patients. The study is available at Moffitt Cancer…
Dr. Paul Sugarbaker joins us for an interview about HIPEC (hyperthermic intraperitoneal chemotherapy) for peritoneal mesothelioma. Paul Sugarbaker, MD, FACS, FRCS, is the Chief of…
Three mesothelioma patients shared their experiences with cancer-related cognitive impairment — also known as “chemo brain” — with Dr. Tracy Vannorsdall, a neuropsychologist at the…
For MesoTV, we brought back a valuable conversation about complementary vs alternative therapies from a previous conference on malignant mesothelioma in New York City. In…
In this video, Jane Churpek, MD, MS, discusses inherited genetics and mesothelioma, in particular as they relate to the BAP1 gene and the BRCA2. Specifically, she covers how…
Elliot Wakeam, MD, discussed mesothelioma treatment at the University of Michigan. Dr. Wakeam is a thoracic and lung transplant surgeon and assistant professor who uses…
Adnan Jaigirdar, MD, FACS, provides an overview of the U.S. Food and Drug Administration (FDA) expanded access program (compassionate use) for investigative therapies for mesothelioma patients. Dr. Jaigirdar is…